iShares Biotechnology ETF $IBB Shares Sold by Audent Global Asset Management LLC

Audent Global Asset Management LLC cut its position in iShares Biotechnology ETF (NASDAQ:IBB) by 12.6% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 22,386 shares of the financial services provider’s stock after selling 3,223 shares during the quarter. iShares Biotechnology ETF accounts for 2.3% of Audent Global Asset Management LLC’s portfolio, making the stock its 18th largest position. Audent Global Asset Management LLC’s holdings in iShares Biotechnology ETF were worth $3,232,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Citigroup Inc. boosted its position in iShares Biotechnology ETF by 27.0% in the 2nd quarter. Citigroup Inc. now owns 4,073,967 shares of the financial services provider’s stock valued at $515,398,000 after buying an additional 865,823 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in shares of iShares Biotechnology ETF by 74.2% in the second quarter. JPMorgan Chase & Co. now owns 833,196 shares of the financial services provider’s stock worth $105,408,000 after acquiring an additional 355,000 shares in the last quarter. Employees Retirement System of Texas purchased a new position in iShares Biotechnology ETF in the second quarter valued at about $25,049,000. Millennium Management LLC boosted its holdings in iShares Biotechnology ETF by 140.8% in the first quarter. Millennium Management LLC now owns 41,676 shares of the financial services provider’s stock valued at $5,330,000 after purchasing an additional 143,893 shares during the last quarter. Finally, Florin Court Capital LLP acquired a new stake in iShares Biotechnology ETF during the 3rd quarter valued at approximately $11,116,000. Hedge funds and other institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Stock Down 1.0%

Shares of IBB opened at $172.43 on Friday. The business’s 50 day moving average is $171.45 and its two-hundred day moving average is $154.43. iShares Biotechnology ETF has a 52-week low of $107.43 and a 52-week high of $179.64.

iShares Biotechnology ETF Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, December 19th. Shareholders of record on Tuesday, December 16th were issued a dividend of $0.1831 per share. The ex-dividend date of this dividend was Tuesday, December 16th. This represents a $0.73 annualized dividend and a yield of 0.4%. This is an increase from iShares Biotechnology ETF’s previous quarterly dividend of $0.08.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.